Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Anti-inflammatory effects:
↓ Platelet aggregation, interferes with kallikrein system, ↓Granulocyte adherence to damaged vasculature, ↓Chemotaxis of PMNs & macrophages
Anti-platelet: ↓ COX-1 & COX-2
Analgesic effects
Antipyretic effects: ↓ COX & IL-1
|
Gastric upset, gastric/duodenal ulcers, hepatotoxicity, asthmatic attacks, rashes, renal toxicity
High doses: salicylism (vomiting, tinnitus, ↓ hearing, vertigo)
|
Used for anti-platelet effect:
↓ incidence of ischemic attacks, unstable angina, coronary artery thrombosis with MI, thrombosis after coronary bypass surgery
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Selectively inhibits COX-2
|
Renal toxicity
↑ risk of thrombotic events
GI upset, peptic ulcers
|
Fewer GI effects and doesn’t affect platelet aggregation; no cardioprotective effects
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Reversibly inhibits both
COX-1 & COX-2
|
Less fluid retention & GI
ulcers
GI upset, peptic ulcers
|
Close the patent ductus arteriosus, analgesia
Anti-inflammatory and anti-platelet action ↓ when used with aspirin
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Nonselective COX inhibitor
Inhibit phospholipase A & C
Reduce neutrophil migration
↓ T cell & B cell proliferation
|
Pancreatitis, headache (25%), psychosis (rarely), thrombocytopenia, aplastic anemia, renal papillary necrosis
GI upset, peptic ulcers
|
Close the patent ductus arteriosus, gout
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Inhibits AICAR* transformylase & thymidate synthase
Affects PMN chemotaxis, DHF
reductase, ↓ proinflammatory cytokines
|
Nausea, mucosal ulcers, hepatotoxicity
CI in pregnancy
|
Rheumatoid arthritis (1st choice)
Juvenile chronic arthritis, psoriasis, ankylosing spondylitis, polymyositis, Wegener’s granulomatosis, lupus, vasculitis
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Inhibits interleukin-1 and 2 receptor production => inhibits macrophage-T-cell interaction and T-cell responsiveness
|
Nephrotoxicity
Hyptension, hyperkalemia, hepatotoxicity, gingival hyperplasia, hirsutisim
|
rheumatoid arthritis (↓ new bony erosions)
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Inhibits dihydroorotate dehydrogenase leading to ↓ ribonucleotide synthesis and arrest of cells in G1 phase => ↓ T-cell proliferation and production of autoantibodies by B cells
↑ IL-10 receptor mRNA, ↓ IL-8 receptor type A mRNA, ↓ TNF-α-dependent NF-κB
|
Diarrhea (25%), ↑ liver enzymes
Mild alopecia, weight gain, ↑BP
CI in pregnancy
|
Rheumatoid arthritis (inhibit bony damage)
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Inhibits CMP dehydrogenase => ↓T-cell proliferation
Interferes w/ WBC adhesion via E&P selectins and ICAM-1
|
Nausea/vomiting,
hypertension, reversible neutropenia
|
Renal disease, vasculitis,
Wegner's granulomatosis, Lupus
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
↓ T-cell response to mitogens
↓ leukocyte chemotaxis
↓ DNA/RNA synthesis
Trap free radicals
|
Ocular toxicity dyspepsia, nausea, vomiting, abdominal pain, rashes, nightmares
|
Malaria, rheumatic disease
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Inhibit immune response
|
Pigmentation changes (anti-rheumatic gold containing compounds)
|
No longer used due to toxicity &
questionable efficacy
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
TNF-α Inhibitors
Human IgG1 anti-TNF antibody that complexes with TNF-α and prevents its interaction with p55 and p75 cell surface receptors => ↓macrophage and T-cell
|
↑risk of bacterial and macrophage-dependent infection (including TB and other opportunistic infections)
|
Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, plaque psoriasis, Crohn’s disease
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
TNF-α Inhibitors
Chimeric IgG1 antibody that binds to soluble and bound TNF-α => ↓macrophage and T-cell function
|
↑incidence of bacterial infections (including upper respiratory), activation of latent TB
|
Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
TNF-α Inhibitors
Fusion protein made of 2 soluble TNF p75 receptor moieties linked to Fc of human IgG1; binds TNF-α and inhibits lymphotoxin-α
|
↑bacterial infections, especially soft tissue infections and septic arthritis, may activate latent TB
|
Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile chronic arthritis, psoriasis
|
|
|
|
Term
|
Definition
CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout
Weak COX 1 and 2 inhibitor in peripheral tissue
Antipyretic and analgesic, but NO anti-inflammatory or platelet aggregation inhibition
|
↑ hepatic enzymes
Overdose: Hepatotoxicity with centrilobular necrosis, acute
renal tubular necrosis
|
Treat moderate pain without anti-inflammatory effect
Preferred over aspirin for children with viral infections hemophiliacs, ulcer-prone patients, gout
|
|
|
|